TVRD INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Group 1 - Faruqi & Faruqi, LLP is investigating potential claims against Tvardi Therapeutics, Inc. following significant losses suffered by investors in Tvardi stock or options [2][5] - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4] - Moonlake Immunotherapeutics experienced a drastic decline in share price, dropping over 80% due to disappointing preliminary data from a Phase 2 clinical trial of TTI-101 [5] Group 2 - The Phase 2 REVERT clinical trial aimed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function in patients with idiopathic pulmonary fibrosis [5] - Preliminary data indicated that the study did not meet its goals, with baseline characteristics being similar across treatment arms, except for a lower percent predicted Forced Vital Capacity (FVC) in placebo-treated patients compared to TTI-101-treated arms [5]